GABA interneurons mediate the rapid antidepressant-like effects of scopolamine
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a recurring psychiatric illness that causes substantial health and socioeconomic burdens. Clinical reports have revealed that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces rapid antidepressant effects in individuals with MDD. Preclinical models suggest that these rapid antidepressant effects can be recapitulated with blockade of M1-type muscarinic acetylcholine receptors (M1-AChR); however, the cellular mechanisms underlying activity-dependent synaptic and behavioral responses to scopolamine have not been determined. Here, we demonstrate that the antidepressant-like effects of scopolamine are mediated by GABA interneurons in the medial prefrontal cortex (mPFC). Both GABAergic (GAD67+) interneurons and glutamatergic (CaMKII+) interneurons in the mPFC expressed M1-AChR. In mice, viral-mediated knockdown of M1-AChR specifically in GABAergic neurons, but not glutamatergic neurons, in the mPFC attenuated the antidepressant-like effects of scopolamine. Immunohistology and electrophysiology showed that somatostatin (SST) interneurons in the mPFC express M1-AChR at higher levels than parvalbumin interneurons. Moreover, knockdown of M1-AChR in SST interneurons in the mPFC demonstrated that M1-AChR expression in these neurons is required for the rapid antidepressant-like effects of scopolamine. These data indicate that SST interneurons in the mPFC are a promising pharmacological target for developing rapid-acting antidepressant therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies in mice indicate that scopolamine, an effective antidepressant medication acting on muscarinic acetylcholine receptors, enacts its antidepressant effects via targeting somatostatin-expressing GABAergic interneurons in mPFC 218”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [218]
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Interneurons of the neocortical inhibitory system
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1519 · Cited by 2,954
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationThe State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Self-citationRajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Self-citation
Research works printed but not linked: 1
- 10.1038/npp.20 · doi:10.1038/npp.20
Cited by
Items 101–144 of 144
HCN channels: New targets for the design of an antidepressant with rapid effects
Luo, P., He, G., & Liu, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.081 · Cited by 12
Teralı, K., Özbeyli, D., Hanoğlu, D. Y., Başer, K. H. C., Şener, G., & Aykaç, A. (2024) · Brain and Behavior · doi:10.1002/brb3.3507 · Cited by 10
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
Munguba, H., Arefin, A., Hasegawa, R., Posa, L., Romano, G. R., Peddada, T., Donatelle, A., Singh, A., Gutzeit, V. A., Vijay, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.04.006 · Cited by 12
Fernandes, G. G., Costa, K. C. M., Scomparin, D. S., Freire, J. B., Guimarães, F. S., & Campos, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782831 · Cited by 9
Wang, Y., Yin, X., He, X., Zhou, C.-M., Shen, J.-C., & Tong, J. (2021) · Aging · doi:10.18632/aging.202684 · Cited by 8
Somatostatin-positive GABAergic interneuron: new targets for depression
Zhang, C., Liu, X., & Yuan, T.-F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.11 · Cited by 9
Wang, Z., Zhou, D., Li, S., Zhang, Y., & Wang, C. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.05.008 · Cited by 8
Piao, J., Chen, H., Piao, X., Cheng, Z., Zhao, F., Cui, R., & Li, B. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106931 · Cited by 8
Mei, Y.-X., Chen, H.-S., Cao, Q.-L., Lv, W., Liu, Y., Deng, S., Zhou, Q., Zhang, Z., Wang, F., Hu, Z., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03239-y · Cited by 10
Cell-type-specific synaptic modulation of mAChR on SST and PV interneurons
Chen, H., He, T., Li, M., Wang, C., Chen, G., Wang, W., Yu, B., Huang, J., Cui, L., Guo, P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1070478 · Cited by 7
Yuan, J., Yao, J.-Q., Fang, X., Dai, W., Wang, Y., Zhang, L., & Li, Y. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00961-2 · Cited by 7
Wei, S., Tang, Y., Wang, F., Wang, Y., & Geng, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1216689 · Cited by 6
Chen, W., Chen, H., Li, Z., Huang, W., & Wu, J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01785-z · Cited by 7
Scopolamine affects fear learning and social recognition in adult zebrafish
Fu, C., Tong, S., Liu, M.-X., Liao, B., & Chou, M.-Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.01.041 · Cited by 5
Physiological markers of rapid antidepressant effects of allopregnanolone
Lambert, P. M., Lu, X., Zorumski, C. F., & Mennerick, S. J. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13023 · Cited by 7
Wang, X., Zhu, X., Ji, X., Yang, J., & Zhou, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s408794 · Cited by 5
Werner, F.-M., & Coveñas, R. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190410165243 · Cited by 5
Fong, T. H., Li, T., Ma, X., Cai, X., & Zhou, Q. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02200-5 · Cited by 4
Guo, C., Wang, C., He, T., Yu, B., Li, M., Zhao, C., Yuan, Y., & Chen, H. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108180 · Cited by 4
Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development
Pannu, A. S., & Goyal, R. K. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328311930240907133618 · Cited by 7
Zhang, B., Tian, J., Jiang, N., Chai, G., Quan, H., Han, X., Xie, H., Zhang, F., Liao, Z., Chen, M., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c02397 · Cited by 3
Kukla, J., Olejnik, P., & Kasarełło, K. (2026) · Molecules · doi:10.3390/molecules31071219 · Cited by 4
The efficacy of scopolamine for patients with Parkinson's disease and depression: Two case reports
Wang, S., Guo, P., Feng, M., Qian, M., Shen, X., & Wang, G. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102107 · Cited by 4
Neurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals
Sharma, B., & Khushboo (2022) · Current Drug Therapy · doi:10.2174/1574885517666220817122840 · Cited by 4
Ajayi, T., Thomas, A., Nikoloc, M., Henderson, L., Zaheri, A., & Dwyer, D. S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1341735 · Cited by 2
Furey, M. L., Drevets, W. C., & Bhattacharya, A. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_8 · Cited by 1
Daher, F., Fukushima, C. T., Ingebretsen, E. A., Bidlack, J. M., Atack, J. R., Popa, M. O., & Fogaça, M. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699507 · Cited by 2
Hales, C., Bartlett, J., Arban, R., Hengerer, B., & Robinson, E. S. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.22.915132
Antidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_26-1 · Cited by 1
Ji, M., Tong, J.-H., Zhou, Z., & Yang, J. (2020) · doi:10.21203/rs.3.rs-21305/v1
Yuhong, W. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.40.006446
Fernandes, G. G. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-28012022-104828
Möhler, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793560282
Duman, R. S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793546101
Self-citationEffect of Somatostatin-Expressing Interneuron Deficits in Depression
郭, 沉. (2019) · Advances in Psychology · doi:10.12677/ap.2019.910214
Antidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_26 · Cited by 1
Ajayi, T., Thomas, A., Nikoloc, M., Henderson, L., Zaheri, A., & Dwyer, D. S. (2023) · Research Square · doi:10.21203/rs.3.rs-2841746/v1
Fong, T. H., Li, T., Ma, X., Cai, X., & Zhou, Q. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.20.619255
Recent advances in rapid-acting antidepressants
Pan, L., He, Y., Wang, G., & Shen, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0157
Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm
Morris, B., & Pratt, J. A. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70582
Research progress on the biological activity and applications of gamma-aminobutyric acid
Tan, Z., Dai, Q., Shen, L., Lei, Y., Wei, F., Ren, F., Hu, S., Chen, Y., Du, Y., & Peng, C. (2026) · Food Research International · doi:10.1016/j.foodres.2026.119601 · Cited by 1
Somatostatin regulation of the stress response
Guo, H., Ali, T., & Li, S. (2026) · Brain medicine : · doi:10.61373/bm026i.0042
Wang, Y., Shi, Y., Chen, Q., Hu, M., Zhao, Y., Ren, W., Liu, K., Hou, F., Cui, Y., Ma, Y., et al. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100601
Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities
Li, H., He, X., Cao, T., Huang, J., Chen, B., Xu, L., Yang, Y., Li, G., & Xiong, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081275
Metadata
- Authors
- Wohleb, E. S., Wu, M., Gerhard, D. M., Taylor, S. R., Picciotto, M. R., Alreja, M., & Duman, R. S.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-06-06
- Volume
- 126
- Issue
- 7
- Pages
- 2482-2494
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4922686
- OpenAlex
- W2415443438
- Cited by
- 144
- References
- 56
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 10 · 2023: 16 · 2022: 12 · 2021: 14 · 2020: 25 · 2019: 20 · 2018: 17 · 2017: 14 · 2016: 1
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- National Institutes of Health (UL1TR001863)
- National Institute of Mental Health (R01MH093897, R37MH045481, R01MH045481, R01MH077681, R01MH105910)
- National Institute of General Medical Sciences (T32GM007324)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- scopolamine, rapid antidepressant effects, major depressive disorder, M1 muscarinic receptor, GABAergic interneurons, somatostatin interneurons, parvalbumin interneurons, medial prefrontal cortex, muscarinic receptor blockade, antidepressant targets
- MeSH terms
- Animals, Antidepressive Agents, Anxiety, Behavior, Animal, Major Depressive Disorder, Electrophysiology, Female, Humans, Interneurons, Male, Mice, Inbred C57BL, Mice, Transgenic, Scopolamine, Prefrontal Cortex, Mice, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.